Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Immunoglobulin Light-chain Amyloidosis 3Burkitt Lymphoma 3Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Smoldering Multiple Myeloma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Plasmacytoma 1Ovarian Neoplasms 1Mastocytosis, Systemic 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia, Plasma Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Hairy Cell 1Intraocular Lymphoma 1Hodgkin Disease 1Hematologic Neoplasms 1Glioma 1Glioblastoma 1Castration-Resistant Prostate Carcinoma 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1Ann Arbor Stage II Mantle Cell Lymphoma 1Anemia 1

Interventions

Dexamethasone 2silmitasertib 1navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1filanesib 1dexamethasone acetate 1dexamethasone 21-phosphate 1carfilzomib 1auricularum 1Steroids 1Specimen Handling 1Sodium Selenite 1Radiotherapy 1Radiation 1Proteasome Inhibitors 1Lenalidomide 1Injections, Subcutaneous 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Calcium Dobesilate 1Bortezomib 1Biopsy 12-(5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-(1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Plasmacytoma × auricularum × Clear all
NCT03031730 2026-02-10

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

National Cancer Institute (NCI)

Phase 1 Terminated
35 enrolled 10 charts
Plasma cell

Multiple Myeloma, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡